Abiraterone and Increased Survival in Metastatic Prostate Cancer

S. de Bono, Johann; J. Logothetis, Christopher; Molina, Arturo; Fizazi, Karim; North, Scott; Chu, Luis; N., Kim; J. Jones, Robert; B. Goodman, Oscar; Saad, Fred; Staffurth, John; N. Mainwaring, Paul; Harland, Stephen; W. Flaig, Thomas; E. Hutson, Thomas; Cheng, Tina; Patterson, Helen; D. Hainsworth, John; J. Ryan, Charles; N. Sternberg, Cora; Ellard, Susan; Fléchon, Aude; N. Saleh, Mansoor; C. Scholz, Mark; Efstathiou, Eleni; Zivi, Andrea; Bianchini, Diletta; Loriot, Yohann; Chieffo, Nicole; Kheoh, Thian; M. Haqq, Christopher; I. Scher, Howard

doi:10.1056/nejmoa1014618

Public

Abiraterone and Increased Survival in Metastatic Prostate Cancer

Published in New England Journal of Medicine • May 25, 2011

Authors:

Johann S. de Bono

Christopher J. Logothetis

Arturo Molina

Abstract

BACKGROUND: Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer ...

Subject

Abiraterone acetate

Medicine

Prednisone

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!